Literature DB >> 12519460

Psychological factors and survival after bone marrow transplantation in patients with leukemia.

Rie Akaho1, Tsukasa Sasaki, Shin-Ichiro Mori, Hideki Akiyama, Miyo Yoshino, Katsuko Hagiya, Kazuyuki Nakagome, Hisashi Sakamaki.   

Abstract

Psychological factors may be associated with the outcome of cancer treatment, including bone marrow transplantation (BMT). However, studies on the issue have provided controversial results. In the present study, effects of mood status on the outcome was studied through a follow-up period of 1-3 years as well as in shorter periods (3 and 8 months) post-BMT in 72 Japanese patients with leukemia. Psychological status was evaluated 2 weeks before BMT using Profile of Mood States (POMS). The most major factor abstracted from the POMS subscales (Factor 1, mainly comprising anxiety, depression, anger, fatigue and confusion) was associated with disease-free survival rate at 3 months post-BMT. However, the factor most significantly associated with the outcome was gender. Females had better outcome than males through the period of 1-3 years as well as at 8 months post-BMT. When analyzed by gender, Factor 1 was associated with poor prognosis at 3 and 8 months in males. In females, however, Factor 1 was not significantly associated with the prognosis. The present results suggest an association between mood status pre-BMT and prognosis post-BMT in a gender-specific manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519460     DOI: 10.1046/j.1440-1819.2003.01084.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  8 in total

Review 1.  'As above, so below' examining the interplay between emotion and the immune system.

Authors:  Samuel Brod; Lorenza Rattazzi; Giuseppa Piras; Fulvio D'Acquisto
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

2.  A mindfulness-based program for improving quality of life among hematopoietic stem cell transplantation survivors: feasibility and preliminary findings.

Authors:  Paul Grossman; Diana Zwahlen; Jorg P Halter; Jakob R Passweg; Claudia Steiner; Alexander Kiss
Journal:  Support Care Cancer       Date:  2014-10-10       Impact factor: 3.603

3.  Consultation-liaison psychiatry: how far have we come?

Authors:  Sherese Ali; Carrie Ernst; Manuel Pacheco; Gregory Fricchione
Journal:  Curr Psychiatry Rep       Date:  2006-06       Impact factor: 5.285

4.  Assessing cognition, depression and anxiety in hospitalized patients during pre and post-Bone Marrow Transplantation.

Authors:  Mina Shirinbakhsh Masule; Mohammad Arbabi; Padideh Ghaeli; Molouk Hadjibabaie; Hasan Torkamandi
Journal:  Iran J Psychiatry       Date:  2014-04

5.  Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia.

Authors:  Tamara E Lacourt; Annemieke Kavelaars; Maro Ohanian; Nina D Shah; Samuel A Shelburne; Andrew Futreal; Dimitrios P Kontoyiannis; Cobi J Heijnen
Journal:  Oncotarget       Date:  2018-07-27

6.  Anxiety and Depression of the Patients with Hematological Malignancies during Hospitalization for Hematopoietic Stem Cell Transplantation.

Authors:  Ho-Jun Seo; Young-Gun Baek; Byung-Sik Cho; Tae-Suk Kim; Yoo Hyun Um; Jeong-Ho Chae
Journal:  Psychiatry Investig       Date:  2019-09-30       Impact factor: 2.505

7.  Pre-transplant depression decreased overall survival of patients receiving allogeneic hematopoietic stem cell transplantation: a nationwide cohort study.

Authors:  Sheng-Min Wang; Sung-Soo Park; Si-Hyun Park; Nak-Young Kim; Dong Woo Kang; Hae-Ran Na; Jong Wook Lee; Seunghoon Han; Hyun Kook Lim
Journal:  Sci Rep       Date:  2020-09-17       Impact factor: 4.379

8.  Intensive patient's care program reduces anxiety and depression as well as improves overall survival in de novo acute myelocytic leukemia patients who underwent chemotherapy: a randomized, controlled study.

Authors:  Hongxia Bao; Yalin Chen; Min Li; Longrui Pan; Xuena Zheng
Journal:  Transl Cancer Res       Date:  2019-02       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.